Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752714 | 0.90 | PPARG (0.39) | BACE1CNR2 | |
| SCHEMBL5755540 | 0.88 | MAPK14 (0.41) | BACE1 | |
| SCHEMBL5752646 | 0.88 | BACE1 (0.43) | BACE1ALDH1A1KDM4EPSMB5BACE2 | |
| SCHEMBL5748432 | 0.87 | NPSR1 (0.37) | BACE1ALDH1A1KDM4ES1PR3DGAT2 | |
| SCHEMBL5754542 | 0.87 | CETP (0.39) | BACE1 | |
| SCHEMBL1900660 | 0.87 | CETP (0.39) | BACE1 | |
| SCHEMBL1900658 | 0.87 | CETP (0.39) | BACE1 | |
| SCHEMBL5752618 | 0.86 | HPGDS (0.37) | BACE1ALDH1A1KDM4EPSMB5CNR2 | |
| SCHEMBL5753546 | 0.85 | HTR1A (0.40) | BACE1ALDH1A1KDM4ECNR2MDM2 | |
| SCHEMBL7122508 | 0.84 | ALDH1A1 (0.41) | BACE1ALDH1A1KDM4EPSMB5CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | BACE1 835/4885ALDH1A1 783/4885KDM4E 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.